Plasma proteomics to identify biomarkers - Application to cardiovascular diseases

Translational Proteomics

Volumn 7, Issue , 2015, Pages 40-48

  Beck, Hans Christian ^a   Overgaard, Martin ^a   Melholt Rasmussen, Lars ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular disease; Plasma; Protein biomarkers; Proteomics

Indexed keywords

ALBUMIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COMPLEMENT FACTOR; CREATINE KINASE; CREATINE KINASE MB; IMMUNOGLOBULIN; MYOGLOBIN; TROPONIN I; TROPONIN T;

ARTICLE; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ELECTROCARDIOGRAM; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; RISK FACTOR; SCREENING TEST; SMOKING;

EID: 84994388432     PISSN: 22129626     EISSN: 22129634     Source Type: Journal    
DOI: 10.1016/j.trprot.2015.01.001     Document Type: Article

References (76)

1. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847. arxiv:/9603539, 10.1161/01.CIR.97.18.1837.
2. Khot U.N., Khot M.B., Bajzer C.T., Sapp S.K., Ohman E.M., Brener S.J., et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003, 290(7):898-904. arxiv:/12928466, 10.1001/jama.290.7.898.
3. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95. Biomarkers Definition Working Group. arxiv:/11240971, 10.1067/mcp.2001.113989.
4. Fox N., Growdon J.H. Biomarkers and surrogates. NeuroRx 2004, 1(2):181. 10.1602/neurorx.1.2.181.
5. Antman E.M., Grudzien C., Sacks D.B. Evaluation of a rapid bedside assay for detection of serum cardiac troponin T. JAMA 1995, 273(16):1279-1282. arxiv:/7715040, 10.1001/jama.1995.03520400049043.
6. de Lemos J.A., Drazner M.H., Omland T., Ayers C.R., Khera A., Rohatgi A., et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010, 304(22):2503-2512. arxiv:/21139111, 10.1001/jama.2010.1768.
7. Saunders J.T., Nambi V., de Lemos J.A., Chambless L.E., Virani S.S., Boerwinkle E., et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation 2011, 123(13):1367-1376. arxiv:/21422391, 10.1161/CIRCULATIONAHA.110.005264.
8. Wang T.J., Wollert K.C., Larson M.G., Coglianese E., McCabe E.L., Cheng S., et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham heart study. Circulation 2012, 126(13):1596-1604. arxiv:/22907935, 10.1161/CIRCULATIONAHA.112.129437.
9. Jaumdally R., Varma C., Macfadyen R.J., Lip G.Y. Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment?. Eur Heart J 2007, 28(8):929-940. arxiv:/17395678, 10.1093/eurheartj/ehm015.
10. Hortin G.L., Sviridov D., Anderson N.L. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 2008, 54(10):1608-1616. arxiv:/18687737, 10.1373/clinchem.2008.108175.
11. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteom 2002, 1(11):845-867. arxiv:/12488461, 10.1074/mcp.R200007-MCP200.
12. Hortin G.L., Sviridov D., Anderson N.L. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 2008, 54(10):1608-1616. arxiv:/18687737, 10.1373/clinchem.2008.108175.
13. Fanali G., di Masi A., Trezza V., Marino M., Fasano M., Ascenzi P. Human serum albumin: from bench to bedside. Mol Aspects Med 2012, 33(3):209-290. arxiv:/22230555, 10.1016/j.mam.2011.12.002.
14. Kristensen L.P., Larsen M.R., Mickley H., Saaby L., Diederichsen A.C., Lambrechtsen J., et al. Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin. J Proteom 2014, 101:141-153. 10.1016/j.jprot.2013.12.011.
15. Conrads T.P., Hood B.L., Veenstra T.D. Sampling and analytical strategies for biomarker discovery using mass spectrometry. BioTechniques 2006, 40(6):799-805. arxiv:/16774124, 10.2144/000112196.
16. Marshall J., Kupchak P., Zhu W., Yantha J., Vrees T., Furesz S., et al. Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res 2003, 2(4):361-372. arxiv:/12938926, 10.1021/pr030003l.
17. Addona T.A., Shi X., Keshishian H., Mani D.R., Burgess M., Gillette M.A., et al. A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat Biotechnol 2011, 29(7):635-643. arxiv:/21685905, 10.1038/nbt.1899.
18. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008, 26(12):1367-1372. arxiv:/19029910, 10.1038/nbt.1511.
19. Sadiq S.T., Agranoff D. Pooling serum samples may lead to loss of potential biomarkers in SELDI-ToF MS proteomic profiling. Proteome Sci 2008, 6:16. arxiv:/18513446, 10.1186/1477-5956-6-16.
20. Neilson K.A., Ali N.A., Muralidharan S., Mirzaei M., Mariani M., Assadourian G., et al. Less label, more free: approaches in label-free quantitative mass spectrometry. Proteomics 2011, 11(4):535-553. arxiv:/21243637, 10.1002/pmic.201000553.
21. Mueller L.N., Brusniak M.Y., Mani D.R., Aebersold R. An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. J Proteome Res 2008, 7(1):51-61. arxiv:/18173218, 10.1021/pr700758r.
22. Boersema P.J., Raijmakers R., Lemeer S., Mohammed S., Heck A.J. Multiplex peptide stable isotope dimethyl labeling for quantitative proteomics. Nat Protoc 2009, 4(4):484-494. arxiv:/19300442, 10.1038/nprot.2009.21.
23. Wiese S., Reidegeld K.A., Meyer H.E., Warscheid B. Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics 2007, 7(3):340-350. arxiv:/17177251, 10.1002/pmic.200600422.
24. Dayon L., Hainard A., Licker V., Turck N., Kuhn K., Hochstrasser D.F., et al. Relative quantification of proteins in human cerebrospinal fluids by MS/MS using 6-plex isobaric tags. Anal Chem 2008, 80(8):2921-2931. arxiv:/18312001, 10.1021/ac702422x.
25. Ow S.Y., Cardona T., Taton A., Magnuson A., Lindblad P., Stensjo K., et al. Quantitative shotgun proteomics of enriched heterocysts from Nostoc sp. PCC 7120 using 8-plex isobaric peptide tags. J Proteome Res 2008, 7(4):1615-1628. arxiv:/18290607, 10.1021/pr700604v.
26. McAlister G.C., Huttlin E.L., Haas W., Ting L., Jedrychowski M.P., Rogers J.C., et al. Increasing the multiplexing capacity of TMTs using reporter ion isotopologues with isobaric masses. Anal Chem 2012, 84(17):7469-7478. arxiv:/22880955, 10.1021/ac301572t.
27. Yin X., Subramanian S., Hwang S.J., O'Donnell C.J., Fox C.S., Courchesne P., et al. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol 2014, 34(4):939-945. arxiv:/24526693, 10.1161/ATVBAHA.113.302918.
28. Anderson L. Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol 2005, 563(1):23-60. arxiv:/15611012, 10.1113/jphysiol.2004.080473.
29. Jones K.A., Kim P.D., Patel B.B., Kelsen S.G., Braverman A., Swinton D.J., et al. Immunodepletion plasma proteomics by tripleTOF 5600 and orbitrap elite/LTQ-Orbitrap Velos/Q exactive mass spectrometers. J Proteome Res 2013, 12(10):4351-4365. arxiv:/24004147, 10.1021/pr400307u.
30. Shi T., Zhou J.Y., Gritsenko M.A., Hossain M., Camp D.G., Smith R.D., et al. IgY14 and SuperMix immunoaffinity separations coupled with liquid chromatography-mass spectrometry for human plasma proteomics biomarker discovery. Methods 2012, 56(2):246-253. arxiv:/21925605, 10.1016/j.ymeth.2011.09.001.
31. Gerszten R.E., Asnani A., Carr S.A. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res 2011, 109(4):463-474. arxiv:/21817166, 10.1161/CIRCRESAHA.110.225003.
32. Boschetti E., Righetti P.G. The art of observing rare protein species in proteomes with peptide ligand libraries. Proteomics 2009, 9(6):1492-1510. arxiv:/19235170, 10.1002/pmic.200800389.
33. Malaud E., Merle D., Piquer D., Molina L., Salvetat N., Rubrecht L., et al. Local carotid atherosclerotic plaque proteins for the identification of circulating biomarkers in coronary patients. Atherosclerosis 2014, 233(2):551-558. arxiv:/24530963, 10.1016/j.atherosclerosis.2013.12.019.
34. Gil-Dones F., Darde V.M., Alonso-Org, Lopez-Almodovar L.F., Mourino-Alvarez L., Padial L.R., et al. Inside human aortic stenosis: a proteomic analysis of plasma. J Proteom 2012, 75(5):1639-1653. arxiv:/22178735, 10.1016/j.jprot.2011.11.036.
35. Warder S.E., Tucker L.A., Strelitzer T.J., McKeegan E.M., Meuth J.L., Jung P.M., et al. Reducing agent-mediated precipitation of high-abundance plasma proteins. Anal Biochem 2009, 387(2):184-193. arxiv:/19454248, 10.1016/j.ab.2009.01.013.
36. Kay R., Barton C., Ratcliffe L., Matharoo-Ball B., Brown P., Roberts J., et al. Enrichment of low molecular weight serum proteins using acetonitrile precipitation for mass spectrometry based proteomic analysis. Rapid Commun Mass Spectrom 2008, 22(20):3255-3260. arxiv:/18803344, 10.1002/rcm.3729.
37. Tian R., Jiang X., Li X., Jiang X., Feng S., Xu S., et al. Biological fingerprinting analysis of the interactome of a kinase inhibitor in human plasma by a chemiproteomic approach. J Chromatogr A 2006, 1134(1-2):134-142. arxiv:/16982065, 10.1016/j.chroma.2006.08.097.
38. Such-Sanmartín G., Ventura-Espejo E., Jensen O.N. Depletion of abundant plasma proteins by poly(N-isopropylacrylamide-acrylic acid) hydrogel particles. Anal Chem 2014, 86(3):1543-1550. arxiv:/24428553, 10.1021/ac403749j.
39. Keshishian H., Addona T., Burgess M., Mani D.R., Shi X., Kuhn E., et al. Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteom 2009, 8(10):2339-2349. arxiv:/19596694, 10.1074/mcp.M900140-MCP200.
40. Keshishian H., Addona T., Burgess M., Kuhn E., Carr S.A. Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteom 2007, 6(12):2212-2229. arxiv:/17939991, 10.1074/mcp.M700354-MCP200.
41. Villén J., Gygi S.P. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nat Protoc 2008, 3(10):1630-1638. arxiv:/18833199, 10.1038/nprot.2008.150.
42. Palmisano G., Lendal S.E., Engholm-Keller K., Leth-Larsen R., Parker B.L., Larsen M.R. Selective enrichment of sialic acid-containing glycopeptides using titanium dioxide chromatography with analysis by HILIC and mass spectrometry. Nat Protoc 2010, 5(12):1974-1982. arxiv:/21127490, 10.1038/nprot.2010.167.
43. Gilar M., Olivova P., Daly A.E., Gebler J.C. Two-dimensional separation of peptides using RP-RP-HPLC system with different pH in first and second separation dimensions. J Sep Sci 2005, 28(14):1694-1703. arxiv:/16224963, 10.1002/jssc.200500116.
44. Hörth P., Miller C.A., Preckel T., Wenz C. Efficient fractionation and improved protein identification by peptide OFFGEL electrophoresis. Mol Cell Proteom 2006, 5(10):1968-1974. arxiv:/16849286, 10.1074/mcp.T600037-MCP200.
45. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008, 117(2):176-184. arxiv:/18086931, 10.1161/CIRCULATIONAHA.107.715698.
46. Virani S.S., Brautbar A., Davis B.C., Nambi V., Hoogeveen R.C., Sharrett A.R., et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the atherosclerosis risk in communities (ARIC) study. Circulation 2012, 125(2):241-249. arxiv:/22128224, 10.1161/CIRCULATIONAHA.111.045120.
47. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342(12):836-843. arxiv:/10733371, 10.1056/NEJM200003233421202.
48. Kosuge M., Ebina T., Ishikawa T., Hibi K., Tsukahara K., Okuda J., et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J 2007, 71(2):186-190. arxiv:/17251664, 10.1253/circj.71.186.
49. Mebazaa A., Vanpoucke G., Thomas G., Verleysen K., Cohen-Solal A., Vanderheyden M., et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J 2012, 33(18):2317-2324. arxiv:/22733835, 10.1093/eurheartj/ehs162.
50. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998, 339(5):321-328. arxiv:/9682046, 10.1056/NEJM199807303390507.
51. Poste G. Bring on the biomarkers. Nature 2011, 469(7329):156-157. arxiv:/21228852, 10.1038/469156a.
52. Drucker E., Krapfenbauer K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J 2013, 4(1):7. arxiv:/23442211, 10.1186/1878-5085-4-7.
53. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56(2):177-185. arxiv:/19884488, 10.1373/clinchem.2009.126706.
54. Meo A.D., Diamandis E.P., Rodriguez H., Hoofnagle A.N., Ioannidis J., Lopez M. What is wrong with clinical proteomics?. Clin Chem 2014, 60:1258-1266. arxiv:/24831563, 10.1373/clinchem.2014.225185.
55. Anderson N.L. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cell Proteom 2005, 4(10):1441-1444. arxiv:/16020426, 10.1074/mcp.I500001-MCP200.
56. Ransohoff D.F. Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer 2005, 5(2):142-149. arxiv:/15685197, 10.1038/nrc1550.
57. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24(8):971-983. arxiv:/16900146, 10.1038/nbt1235.
58. Carr S.A., Anderson L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory?. Clin Chem 2008, 54(11):1749-1752. arxiv:/18957555, 10.1373/clinchem.2008.114686.
59. Anderson N.L. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010, 56(2):177-185. arxiv:/19884488, 10.1373/clinchem.2009.126706.
60. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh C., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355(25):2631-2639. arxiv:/17182988, 10.1056/NEJMoa055373.
61. Raizada A., Bhandari S., Khan M.A., Singh H.V., Thomas S., Sarabhai V., et al. Brain type natriuretic peptide (BNP) - a marker of new millennium in diagnosis of congestive heart failure. Indian J Clin Biochem 2007, 22(1):4-9. arxiv:/23105644, 10.1007/BF02912873.
62. Kambayashi Y., Nakao K., Kimura H., Kawabata T., Nakamura M., Inouye K., et al. Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun 1990, 173(2):599-605. arxiv:/2260971, 10.1016/S0006-291X(05)80077-4.
63. Kambayashi Y., Nakao K., Mukoyama M., Saito Y., Ogawa Y., Shiono S., et al. Isolation and sequence determination of human brain natriuretic peptide in human atrium. FEBS Lett 1990, 259(2):341-345. arxiv:/2136732, 10.1016/0014-5793(90)80043-I.
64. Shapiro B.P., Chen H.H., Burnett J.C., Redfield M.M. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc 2003, 78(4):481-486. arxiv:/12683700, 10.4065/78.4.481.
65. Wilkinson J.M., Grand R.J. Comparison of amino acid sequence of troponin I from different striated muscles. Nature 1978, 271(5640):31-35. arxiv:/146828, 10.1038/271031a0.
66. Adams J.E., Bodor G.S., Davila-Roman V.G., Delmez J.A., Apple F.S., Ladenson J.H., et al. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation 1993, 88(1):101-106. arxiv:/8319322, 10.1161/01.CIR.88.1.101.
67. Capellan O., Hollander J.E., Pollack C., Hoekstra J.W., Wilke E., Tiffany B., et al. Prospective evaluation of emergency department patients with potential coronary syndromes using initial absolute CK-MB vs. CK-MB relative index. J Emerg Med 2003, 24(4):361-367. arxiv:/12745035, 10.1016/S0736-4679(03)00030-1.
68. Arroyo-Espliguero R., Avanzas P., Cosín-Sales J., Aldama G., Pizzi C., Kaski J.C. C-reactive protein elevation and disease activity in patients with coronary artery disease. Eur Heart J 2004, 25(5):401-408. arxiv:/15033252, 10.1016/j.ehj.2003.12.017.
69. Hung M.J., Cherng W.J., Yang N.I., Cheng C.W., Li L.F. Relation of high-sensitivity C-reactive protein level with coronary vasospastic angina pectoris in patients without hemodynamically significant coronary artery disease. Am J Cardiol 2005, 96(11):1484-1490. arxiv:/16310426, 10.1016/j.amjcard.2005.07.055.
70. Shah S.J., Marcus G.M., Gerber I.L., McKeown B.H., Vessey J.C., Jordan M.V., et al. High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. J Card Fail 2006, 12(1):61-65. arxiv:/16500582, 10.1016/j.cardfail.2005.08.003.
71. Braunwald E., Antman E.M., Beasley J.W., Califf R.M., Cheitlin M.D., Hochman J.S., et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with unstable angina). J Am Coll Cardiol 2002, 40(7):1366-1374. arxiv:/12383588, 10.1016/S0735-1097(02)02336-7.
72. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82(2):495-506. arxiv:/2372896, 10.1161/01.CIR.82.2.495.
73. Stubbs P., Seed M., Lane D., Collinson P., Kendall F., Noble M. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes. Eur Heart J 1998, 19(9):1355-1364. arxiv:/9792261, 10.1053/euhj.1998.1043.
74. Seed M., Doherty E., Stubbs P. Lipoprotein (a): a prothrombotic risk factor for coronary artery disease. J Cardiovasc Risk 1995, 2(3):206-215. arxiv:/7584795, 10.1097/00043798-199506000-00005.
75. Benn M., Nordestgaard B.G., Jensen G.B., Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B: the Copenhagen City Heart Study. Arterioscler Thromb Vasc Biol 2007, 27(3):661-670. arxiv:/17170368, 10.1161/01.ATV.0000255580.73689.8e.
76. McQueen M.J., Hawken S., Wang X., Ounpuu S., Sniderman A., Probstfield J., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372(9634):224-233. arxiv:/18640459, 10.1016/S0140-6736(08)61076-4.